Sub Subramony, M.D., discusses how the modified Friedreich Ataxia Rating Scale (mFARS) is valuable for monitoring disease progression in clinical trials and its applicability in everyday clinical practice for assessing patient status.
Video content above is prompted by the following:
The modified Friedreich Ataxia Rating Scale (mFARS) has been developed to monitor FA disease progression in clinical trials. Is mFARS useful in your everyday clinical practice?
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
December 11th 2025Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies.
Read More
Transforming Alzheimer Disease Research Into Real-World Care: Q&A With B. Joy Snider, MD, PhD
December 10th 2025In 2025, each issue of Population Health, Equity & Outcomes has featured a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with B. Joy Snider, MD, PhD, professor of neurology at Washington University in St Louis.
Read More